سعر نابليما 20مجم 30 قرص 2026

Naplema rosuvastatin 20 mg film-coated tablets, 30 tablets (Napco); HMG-CoA reductase inhibitor for hypercholesterolaemia and cardiovascular risk reduction.

• To reduce the risk of major adverse cardiovascular events (CV death, nonfatal myocardial infarction, nonfatal stroke or arterial revascularization) in adults at increased risk.Population: AdultsDailyMed (U.S. National Library of Medicine)
• As an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia (and to slow progression of atherosclerosis), and in heterozygous (≥8 years) or homozygous (≥7 years) familial hypercholesterolemia.DailyMed (U.S. National Library of Medicine)

• Most frequent adverse reactions (≥2%): headache, nausea, myalgia, asthenia and constipation.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Acute liver failure or decompensated cirrhosis.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to rosuvastatin or any excipient (rash, pruritus, urticaria, angioedema have been reported).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Myopathy and rhabdomyolysis (with possible acute kidney injury) may occur; risk factors include age ≥65, uncontrolled hypothyroidism, renal impairment, certain concomitant drugs, higher doses and Asian ancestry.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Immune-mediated necrotizing myopathy has been reported rarely with statins; discontinue if suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hepatic dysfunction: transaminase increases and rare fatal or non-fatal hepatic failure have been reported.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• GemfibrozilAvoid concomitant use; if unavoidable, start rosuvastatin 5 mg once daily and do not exceed 10 mg once daily.DailyMed (U.S. National Library of Medicine)
• Sofosbuvir/velpatasvir/voxilaprevir or ledipasvir/sofosbuvirAvoid concomitant use (increased rosuvastatin exposure and myopathy risk).DailyMed (U.S. National Library of Medicine)
• WarfarinObtain INR before starting rosuvastatin and monitor frequently until stable after initiation, titration or discontinuation.DailyMed (U.S. National Library of Medicine)

• Discontinue rosuvastatin when pregnancy is recognized (or consider the patient's ongoing therapeutic needs); based on its mechanism of action it may cause fetal harm, and treatment of hypercholesterolemia is not generally necessary during pregnancy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Limited data indicate rosuvastatin is present in human milk; because of the potential for serious adverse reactions in the infant, breastfeeding is not recommended during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Rosuvastatin: Competitive inhibition of HMG-CoA reductase reduces hepatic cholesterol synthesis and increases LDL-receptor expression.